Clinical Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hahm, H. A.
Right arrow Articles by Davidson, N. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hahm, H. A.
Right arrow Articles by Davidson, N. E.
Clinical Cancer Research Vol. 7, 391-399, February 2001
© 2001 American Association for Cancer Research


Experimental Therapeutics, Preclinical Pharmacology

Combination of Standard Cytotoxic Agents with Polyamine Analogues in the Treatment of Breast Cancer Cell Lines1

Hillary A. Hahm2, Valerie R. Dunn, Kimberly A. Butash3, Wendy L. Deveraux, Patrick M. Woster, Robert A. Casero, Jr. and Nancy E. Davidson4

The Johns Hopkins Oncology Center, Johns Hopkins University, Baltimore, Maryland 21231 [H. A. H., V. R. D., K. A. B., W. L. D., R. A. C., N. E. D.], and Wayne State University, Detroit, Michigan 48202 [P. M. W.]

Polyamines are essential for cell growth and differentiation. Structural polyamine analogues have been shown to have antitumor activity in experimental models including breast cancer. The ability of polyamine analogues to alter activity of cytotoxic chemotherapeutic agents in breast cancer models has not been evaluated. This study evaluates the ability of two polyamine analogues, N1-ethyl-N11-[(cyclopropyl)methyl]-4,8-diazaundecane (CPENSpm) and N1-ethyl-N11-[(cycloheptyl)methyl]4,8-diazaundecane (CHENSpm) to synergize with cytotoxics in five human breast cancer cell lines. Antagonism, additivity, or synergy of the combinations was determined using the median effect/combination index model. The chemotherapeutic agents chosen, cisdiaminechloroplatinum(II), doxorubicin, 5-fluorouracil, fluorodeoxyuridine, 4-hydroperoxycyclophosphamide, paclitaxel, docetaxel, and vinorelbine, all have antitumor activity in breast cancer and represent a spectrum of mechanisms. Three treatment schedules of polyamine analogue and cytotoxic were tested in MCF-7 and MDA-MB-468 lines, demonstrating a schedule-dependence of synergistic growth inhibition. Cytotoxic agent alone for 24 h followed by polyamine analogue alone for 96 h resulted in the most synergistic combinations and the greatest synergy. This schedule was then tested in three additional breast cancer lines, and several synergistic combinations were again identified. Two cytotoxics, vinorelbine and the fluoropyrimidines, showed the most promise in combination with the polyamine analogues. They were able to synergize with one or both polyamine analogues in most of the breast cancer cell lines. CPENSpm was also able to synergize with virtually all of the cytotoxics in the estrogen receptor {alpha}-positive MCF-7 and T-47D lines. These preclinical data demonstrate a treatment schedule and combinations of polyamine analogues and cytotoxics that will be important to study mechanistically and clinically for breast cancer.




This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
A. Pledgie-Tracy, M. D. Sobolewski, and N. E. Davidson
Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines
Mol. Cancer Ther., March 1, 2007; 6(3): 1013 - 1021.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
W. L. Allen, E. G. McLean, J. Boyer, A. McCulla, P. M. Wilson, V. Coyle, D. B. Longley, R. A. Casero Jr., and P. G. Johnston
The role of spermidine/spermine N1-acetyltransferase in determining response to chemotherapeutic agents in colorectal cancer cells
Mol. Cancer Ther., January 1, 2007; 6(1): 128 - 137.
[Abstract] [Full Text] [PDF]


Home page
J BiochemHome page
Y. Wang and R. A. Casero Jr.
Mammalian Polyamine Catabolism: A Therapeutic Target, a Pathological Problem, or Both?
J. Biochem., January 1, 2006; 139(1): 17 - 25.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Pledgie, Y. Huang, A. Hacker, Z. Zhang, P. M. Woster, N. E. Davidson, and R. A. Casero Jr.
Spermine Oxidase SMO(PAOh1), Not N1-Acetylpolyamine Oxidase PAO, Is the Primary Source of Cytotoxic H2O2 in Polyamine Analogue-treated Human Breast Cancer Cell Lines
J. Biol. Chem., December 2, 2005; 280(48): 39843 - 39851.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
G. Marverti, M. G. Monti, A. E. Pegg, D. E. McCloskey, S. Bettuzzi, A. Ligabue, A. Caporali, D. D'Arca, and M. S. Moruzzi
Spermidine/spermine N1-acetyltransferase transient overexpression restores sensitivity of resistant human ovarian cancer cells to N1,N12-bis(ethyl)spermine and to cisplatin
Carcinogenesis, October 1, 2005; 26(10): 1677 - 1686.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
Y. Huang, J. C. Keen, E. Hager, R. Smith, A. Hacker, B. Frydman, A. L. Valasinas, V. K. Reddy, L. J. Marton, R. A. Casero Jr., et al.
Regulation of Polyamine Analogue Cytotoxicity by c-Jun in Human MDA-MB-435 Cancer Cells
Mol. Cancer Res., February 1, 2004; 2(2): 81 - 88.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. C. Wolff, D. K. Armstrong, J. H. Fetting, M. K. Carducci, C. D. Riley, J. F. Bender, R. A. Casero Jr., and N. E. Davidson
A Phase II Study of the Polyamine Analog N1,N11-Diethylnorspermine (DENSpm) Daily for Five Days Every 21 Days in Patients with Previously Treated Metastatic Breast Cancer
Clin. Cancer Res., December 1, 2003; 9(16): 5922 - 5928.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Y. Huang, E. R. Hager, D. L. Phillips, V. R. Dunn, A. Hacker, B. Frydman, J. A. Kink, A. L. Valasinas, V. K. Reddy, L. J. Marton, et al.
A Novel Polyamine Analog Inhibits Growth and Induces Apoptosis in Human Breast Cancer Cells
Clin. Cancer Res., July 1, 2003; 9(7): 2769 - 2777.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.